With a client base representing companies from the FT Global 500 and FTSE listed companies, Reddie & Grose is recognised as a leading patent and trade mark firm. In 2009, the Managing Intellectual Property global patent survey ranked the firm as one of the UK’s top patent prosecution advisors. It consistently continues to achieve high rankings in all professional surveys.. . Reddie & Grose prides itself on delivering intellectual property protection for businesses in both the domestic and international marketplaces with a strong professional team of over 30 people from varied scientific backgrounds.. . The firm’s Cambridge office offers particular expertise in biotechnology, pharmaceutical, chemical, engineering, cleantech, instrumentation, medical device, materials, and software related inventions. Companies/academic institutions represented in this field by Reddie & Grose include: Diagnostics for the Real World, Haemostatix, Funxional Therapeutics, TCP Innovations, Trillion Genomics, Brax, Cambridge Biopolymers, Metalysis, University of Cambridge, Cambridge Broadband, i2, Cambridge Biotechnology Ltd and nCipher.. . Talk to us...
Watch our webinar with One Nucleus 'What are the IP Challenges at the Intersection of Life Sciences, Technology and Engineering Disciplines?' https://youtu.be/OHM3IoLoJ0Q
Watch our webinar with One Nucleus 'What are the IP Challenges at the Intersection of Life Sciences, Technology and Engineering Disciplines?' https://youtu.be/OHM3IoLoJ0Q
Horizon Discovery Group plc, a UK headquartered global life science company, is a world leader in gene editing and gene modulation. Through the application of these technologies the Company enables researchers to alter almost any gene or modulate its function in human or mammalian cells to generate models that mimic the genetic abnormalities found in diseases such as cancer. Horizon offers a catalogue of over 1,000,000 cell and reagent products, which along with related research services, support a greater understanding of the function of genes across all species and the genetic drivers of disease, and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, and are used in the Company’s own R&D pipeline.. . Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”. https://www.horizondiscovery.com . . •
Ride Therapeutics is a recently formed transatlantic biotechnology company with the mission of unlocking the full potential of mRNA & gene editing therapeutics through targeted & tunable delivery of these modalities. Founded by world-leading scientists from Harvard University & the University of Cambridge, Ride’s unique technology platform provides an entirely new approach to solving the delivery challenge at the molecular level. Powered by micro- and nano-engineering coupled to advanced data science, Ride is building the capability to deliver any molecular cargo, to any cell type, with a tunable release profile.
Riverlabs is a new and exciting 28-acre life sciences campus, ideally situated at the centre of the ‘Golden Triangle’ in Ware, Hertfordshire. 440,000 sq ft (GIA) will be available in three phases:
• The most affordable, existing, purpose-built R&D space in the ‘Golden Triangle’. An intelligent refresh will transform existing labs into a modern, welcoming and sustainable working environment with staff wellbeing at its heart.
• Available for fit-out in January 2023, Riverlabs 1 provides 141,423 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Available for fit-out in May 2023, Riverlabs 2 provides 219,900 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Set within a unique, open campus environment enjoying natural waterfront to the River Lea. 15 acres of open green space plus sports club, tennis courts, cricket pitch, five-a-side football, access to water-based activities, river walks and nature on the doorstep.
• Perfectly positioned in an established life sciences ecosystem. Home to GSK for 50+ years, and within a 45-minute radius of major life science clusters in London, Cambridge and Stevenage, providing a huge pool of life sciences talent to recruit from.
To find out more visit https://www.riverlabsware.com
• The most affordable, existing, purpose-built R&D space in the ‘Golden Triangle’. An intelligent refresh will transform existing labs into a modern, welcoming and sustainable working environment with staff wellbeing at its heart.
• Available for fit-out in January 2023, Riverlabs 1 provides 141,423 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Available for fit-out in May 2023, Riverlabs 2 provides 219,900 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Set within a unique, open campus environment enjoying natural waterfront to the River Lea. 15 acres of open green space plus sports club, tennis courts, cricket pitch, five-a-side football, access to water-based activities, river walks and nature on the doorstep.
• Perfectly positioned in an established life sciences ecosystem. Home to GSK for 50+ years, and within a 45-minute radius of major life science clusters in London, Cambridge and Stevenage, providing a huge pool of life sciences talent to recruit from.
To find out more visit https://www.riverlabsware.com
No data available
RxCelerate is an outsourced drug development platform specialising in bespoke experimental design with data-rich end-points. We can drive your asset through drug discovery, medicinal chemistry, preclinical research and beyond, maximising your chances of reaching the clinic. RxCelerate offers comprehensive investigation packages and stand-alone assays with in-built flexibility, making it the perfect partner for both virtual, asset-centric companies and large pharmaceutical companies seeking to outsource elements of their project. We combine client consultation with in-house expertise to ensure that our in vitro design and preclinical models are robust and information rich, improving both compund progression and translational capacity.